Biomarker Deals: Terms, Value and Trends, 2008-2018

Jan 2019| BIO169A| BCC Publishing

Report Highlights

Over the last decade, biomarker research has become one of the essential aspects not only of the in vitro diagnostics industry but an important component of the drug discovery and development process. Moreover, with the growing trend in personalized medicine and companion diagnostics, the use of biomarkers is becoming obligatory in management of certain diseases, such as cancer drug regimen.

Report Includes

  • 43 data tables and 42 additional tables
  • An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including detailed analysis of deals structure and their potential values
  • Information about significant players in this field of study, trends and obstacles, and other information affecting biomarker market development
  • Review of business terms and conditions of deals in the biomarker market, with focus on major trends in biomarker deal making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
  • Essential information to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
  • Identification of the main elements in licensing, acquisitions and partnership deals in the biomarker industry
  • Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis et al.
  • Details of various types of biomarkers deals and milestone payments and their value in different deals
  • Examination of competitive landscape and detailed profiles of major companies developing biomarkers, including bioMérieux SA, IntegraGen SA, MDxHealth, Myriad Genetics, Protagen AG and Qiagen

Report Scope

This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U. S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.

Frequently Asked Questions (FAQs)

Analyst Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
. Title/Chapter NamePagesPrice Member Price
Full Report: Biomarker Deals: Terms, Value and Trends, 2008-2018116 $2,750 Free
Chapter- 1: Introduction2Free
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Market and Technology Background21$498Free
Chapter- 4: Biomarkers Market - Licensing, Acquisitions, Collaborations Deal Analysis53$1,256Free
Chapter- 5: Impact of Other Markets and Clinical Trials on Licensing, Acquisition and Collaborations in the Biomarkers Market21$498Free
Chapter- 6: Patent Review/New Developments8$190Free
Chapter- 7: Market Summary4$95Free
Chapter- 8: Company Profiles5$119Free
Biomarker Deals: Terms, Value and Trends, 2008-2018

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries